We recently met with Alzheimer’s patient, Herb during his second treatment of disruptive breakthrough drug, TB006, a humanized monoclonal antibody developed by TrueBinding, Inc. that helps the brain fight inflammation and naturally break up amyloid plaques contributing to cognitive decline and memory loss; also an FDA-Approved clinical trial program and one of the 50+ cognitive decline therapies available at Alzheimer’s Treatment Centers of America.
Herb was first diagnosed with Alzheimer’s in 2021 by his neurologist, however his family, including wife and life partner, Beth, noticed a decline in his cognition and memory loss years before that. Sadly, such is the case for many of our patients, which is why we offer a FREE 7-minute cognitive and memory status screening to those seeking answers and hope.
“This treatment is bringing my Herb back.” — Beth, caregiver and wife
Beth, also playing the role as Herb’s primary caregiver, elaborates on her reaction when she learned of his diagnosis. “Hopeless. Lost. I thought we would enjoy a peaceful twilight together with cruises, and spoiling grandchildren. He couldn’t remember that he had grandchildren. I didn’t think life would take this turn, and I truly felt hopeless.” Beth says as she recounts the moment Herb was officially diagnosed with Alzheimer’s Disease including general aphasia.
Having undergone many of the par-for-the-course-treatments for this relentless disease, Beth was prepared and ready to accept that “this is what life is now,” and to prepare herself for Herb’s further decline. Until she called Alzheimer’s Treatment Centers of America, and learned of the innovative treatments we offer, including TB006.
What is TB006 and How Does It Work to Treat Alzheimer’s Disease?
TB006 is an investigational monoclonal antibody therapy currently under clinical evaluation for the treatment of Alzheimer’s disease. It is designed to target and neutralize Galectin-3, a protein that plays a key role in promoting neuroinflammation and the buildup of toxic plaques associated with cognitive decline. In Alzheimer’s disease, chronic inflammation and the aggregation of abnormal proteins such as amyloid-beta and tau contribute significantly to neuronal damage. By inhibiting Galectin-3, TB006 aims to reduce this harmful inflammation and slow the progression of neurodegeneration. Early clinical data has shown promising outcomes, particularly in patients with early-stage Alzheimer’s or mild cognitive impairment (MCI), where TB006 may help stabilize or improve cognitive function. The therapy is currently being tested in FDA-approved clinical trials as part of a larger, multi-modal approach to combat Alzheimer’s disease, and is available to qualifying patients at Alzheimer’s Treatment Centers of America (ATCA).
But for Herb and Beth, TB006 has been so much more than just another investigational treatment. Though Herb has only undergone one session of TB006 therapy, a once monthly IV treatment administered by our expert medical staff in the Port St. Lucie clinic, Beth has noticed a world of improvement over just four weeks.
Beth reports that prior to starting TB006, Herb was experiencing more “bad days” than “good” ones. She says she can tell by the way he “shuffles his feet in the morning.” Beth also reports that his tremors (a symptom often experienced by Alzheimer’s patients) have subsided, he is no longer experiencing incontinence (also another common struggle), and he can remember his children’s birth dates (and birth years!) again! With tears of joy and hope welling in her eyes, she explained that this treatment “is bringing her Herb back.”
Beth's Message to Others
“Don’t lose hope. Call the folks at ATCA as soon as today to be evaluated for treatment. It’s been an unrelenting four years of dangerous and unsuccessful therapies and pharmaceuticals that showed no results, and with TB006, we’re seeing incredible results in just one month.”
Follow Herb’s journey with us, as ATCA continues to treat Herb’s Alzheimer’s disease and cognitive impairment. And if you or your loved one is experiencing challenges similar to Herb’s, make the call to ATCA today – Simply dial #250 and use keyword “memory loss” to be connected to our cognitive care team, or enroll in our FREE 7-minute cognitive and memory status screening here.
#herbsjourney #atca #TB006 #alzheimerstreatment #alzheimersawarenessmonth #memoriesmatter #alzheimers #alzheimerstherapy #alzheimersdisease